Carol B Hanna1, Shan Yao1, Cathy M Ramsey1, Jon D Hennebold2, Mary B Zelinski1, Jeffrey T Jensen3. 1. Division of Reproductive and Developmental Science, Oregon National Primate Research Center, Beaverton, OR 97006, USA. 2. Division of Reproductive and Developmental Science, Oregon National Primate Research Center, Beaverton, OR 97006, USA; Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR 97239, USA. 3. Division of Reproductive and Developmental Science, Oregon National Primate Research Center, Beaverton, OR 97006, USA; Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR 97239, USA. Electronic address: jensenje@ohsu.edu.
Abstract
OBJECTIVE: Studies in mice suggest that cilostazol, an FDA-approved phosphodiesterase 3 (PDE3) inhibitor, might have a contraceptive effect within the approved dose range. We sought to evaluate the potential contraceptive effects of cilostazol in a nonhuman primate model. STUDY DESIGN: Adult female rhesus macaques were stimulated to develop multiple preovulatory follicles by administering human recombinant gonadotropins, and oocytes were collected by follicle aspiration 36 h after an ovulatory stimulus (human chorionic gonadotropin). Monkeys received no further treatment (controls) or the PDE3 inhibitor cilostazol at the maximum approved human dose of 100mg twice daily starting 6 days prior to follicle aspiration. Recovered oocytes were scored for meiotic stage [germinal vesicle (GV) intact, GV breakdown], and metaphase II stage oocytes were fertilized in vitro and observed for normal embryo development. RESULTS: Similar proportions of GV stage oocytes were recovered from control (27%±4%) and cilostazol (27%±9%)-treated females, and the proportion of embryos that developed into blastocysts was also similar for both groups (7%±5% control vs. 15%±8% cilostazol). CONCLUSION: Oral dosing of cilostazol tablets during controlled ovarian stimulation protocols did not prevent oocyte maturation or embryo development in macaques. IMPLICATIONS: Since administration of the maximum approved human dose of cilostazol (an FDA-approved PDE3 inhibitor) to macaques did not prevent oocyte maturation or fertilization, it is not likely that this dose would be contraceptive in women.
OBJECTIVE: Studies in mice suggest that cilostazol, an FDA-approved phosphodiesterase 3 (PDE3) inhibitor, might have a contraceptive effect within the approved dose range. We sought to evaluate the potential contraceptive effects of cilostazol in a nonhuman primate model. STUDY DESIGN: Adult female rhesus macaques were stimulated to develop multiple preovulatory follicles by administering human recombinant gonadotropins, and oocytes were collected by follicle aspiration 36 h after an ovulatory stimulus (human chorionic gonadotropin). Monkeys received no further treatment (controls) or the PDE3 inhibitor cilostazol at the maximum approved human dose of 100mg twice daily starting 6 days prior to follicle aspiration. Recovered oocytes were scored for meiotic stage [germinal vesicle (GV) intact, GV breakdown], and metaphase II stage oocytes were fertilized in vitro and observed for normal embryo development. RESULTS: Similar proportions of GV stage oocytes were recovered from control (27%±4%) and cilostazol (27%±9%)-treated females, and the proportion of embryos that developed into blastocysts was also similar for both groups (7%±5% control vs. 15%±8% cilostazol). CONCLUSION: Oral dosing of cilostazol tablets during controlled ovarian stimulation protocols did not prevent oocyte maturation or embryo development in macaques. IMPLICATIONS: Since administration of the maximum approved human dose of cilostazol (an FDA-approved PDE3 inhibitor) to macaques did not prevent oocyte maturation or fertilization, it is not likely that this dose would be contraceptive in women.
Authors: Jeffrey T Jensen; Mary B Zelinski-Wooten; Kristine M Schwinof; Jessica E Vance; Richard L Stouffer Journal: Contraception Date: 2005-01 Impact factor: 3.375
Authors: Jeffrey T Jensen; Mary B Zelinski; Jessica E Stanley; John W Fanton; Richard L Stouffer Journal: Contraception Date: 2008-03-04 Impact factor: 3.375
Authors: Rachael P Norris; William J Ratzan; Marina Freudzon; Lisa M Mehlmann; Judith Krall; Matthew A Movsesian; Huanchen Wang; Hengming Ke; Viacheslav O Nikolaev; Laurinda A Jaffe Journal: Development Date: 2009-06 Impact factor: 6.868
Authors: Rachael P Norris; Marina Freudzon; Lisa M Mehlmann; Ann E Cowan; Alexander M Simon; David L Paul; Paul D Lampe; Laurinda A Jaffe Journal: Development Date: 2008-10 Impact factor: 6.868
Authors: Ahmed M Taiyeb Albarzanchi; Christie M Sayes; Mundhir T Ridha Albarzanchi; Virginia R Fajt; W Les Dees; Duane C Kraemer Journal: Contraception Date: 2012-10-22 Impact factor: 3.375
Authors: Cecily V Bishop; Taylor E Reiter; David W Erikson; Carol B Hanna; Brittany L Daughtry; Shawn L Chavez; Jon D Hennebold; Richard L Stouffer Journal: J Assist Reprod Genet Date: 2019-06-11 Impact factor: 3.412
Authors: Weiping Su; Steven Matsumoto; Fatima Banine; Taasin Srivastava; Justin Dean; Scott Foster; Peter Pham; Brian Hammond; Alec Peters; Kesturu S Girish; Kanchugarakoppal S Rangappa; Joachim Jose; Jon D Hennebold; Melinda J Murphy; Jill Bennett-Toomey; Stephen A Back; Larry S Sherman Journal: Glia Date: 2019-09-06 Impact factor: 7.452